Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Harris

Allergy & Immunology South Bend, IN Medical Doctor

NPI 1275523722 CMS profile 1025870

211 N Eddy St, South Bend, IN 46617

Open in the dashboard

General payments

$1,311

52 records reported · program years 2019–2025

Research payments

$8,710

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$1,455,915

7 holdings reported · through program year 2025

Research they led as principal investigator

$1,606,945 paid to institutions, not to them · program years 2019–2024

Through program year 2025, James Harris of South Bend, IN is reported in the CMS Open Payments database as having received $1,311 across 52 general payments and $8,710 in research payments paid to them. Separately, studies naming them as principal investigator received $1,606,945 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,455,915 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

15 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $124 1
2024 General $366 16
2023 General $405 19
2022 General $65 4
2021 General $270 7
2020 General $22 1
2019 General $59 4
2019 Research $8,710 3
2025 Ownership $109,356 1
2024 Ownership $109,356 1
2023 Ownership $106,913 1
2022 Ownership $154,321 1
2021 Ownership $88,340 1
2020 Ownership $80,643 1
2019 Ownership $806,985 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Harris
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to James Harris were reported at $124. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year James Harris Allergy & Immunology median Middle half National median
2019 $59 $594 $163–$1,512 $163
2020 $22 $426 $106–$1,233 $114
2021 $270 $638 $157–$1,708 $132
2022 $65 $790 $205–$1,961 $149
2023 $405 $852 $220–$2,147 $160
2024 $366 $865 $203–$2,267 $164
2025 $124 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $515 18 payments
  2. Genentech USA, Inc. $190 9 payments
  3. Regeneron Healthcare Solutions, Inc. $163 9 payments
  4. Pfizer Inc. $136 2 payments
  5. Biohaven Pharmaceuticals, Inc. $61 1 payment
  6. AbbVie, Inc. $46 2 payments
  7. AstraZeneca Pharmaceuticals LP $45 2 payments
  8. BioCryst US Sales Co., LLC $24 1 payment
  9. Teva Pharmaceuticals USA, Inc. $22 1 payment
  10. Zimmer Biomet Holdings, Inc. $20 1 payment
  11. Other $88 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,311 52 payments
Products named General payments · program years 2019–2025
  1. NUCALA $442 10 payments
  2. Xolair $190 9 payments
  3. DUPIXENT $163 9 payments
  4. NURTEC ODT Pain $124 1 payment
  5. TRELEGY ELLIPTA $73 8 payments
  6. NURTEC ODT Primary Care $61 1 payment
  7. RINVOQ $46 2 payments
  8. FASENRA $24 1 payment
  9. Orladeyo $24 1 payment
  10. AIRSUPRA $21 1 payment
  11. Other $120 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biotest AG $8,710 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,594

Median for Allergy/ Immunology: 449

Drug cost

$326,729

Median for Allergy/ Immunology: $169,700

Branded share of claims

31.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 80 $80,277
Tezspire Tezepelumab-Ekko Brand 15 $63,818
Nucala Mepolizumab Brand 11 $47,110
Breo Ellipta Fluticasone/Vilanterol Brand 70 $37,974
Cromolyn Sodium Generic 20 $23,016
Symbicort Budesonide/Formoterol Fumarate Brand 46 $15,843
Spiriva Respimat Tiotropium Bromide Brand 13 $12,221
Methscopolamine Bromide Generic 33 $7,843
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 50 $5,246
Hydroxyzine Hcl Generic 212 $5,117

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$76,171

Of which drugs: $60,806

Medicare patients

163

Average age 69

Services billed

3,448

121 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 58%
Depression 20%
Diabetes 16%
Ischemic heart disease 16%
COPD 15%
Osteoporosis 15%
Chronic kidney disease 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $143
$143 11 —
Xolair
  • Genentech USA, Inc. $107
$107 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $42
$42 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $35
$35 80 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record